Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$32.68 USD
+0.11 (0.34%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $32.70 +0.02 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VKTX 32.68 +0.11(0.34%)
Will VKTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Other News for VKTX
Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Viking Therapeutics Q2: Confidently Continuing The Recovery
Viking Therapeutics Receives Buy Rating Amid Promising Clinical Developments and Strategic Initiatives